Andrx Fortamet Paragraph IV Certifications
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval of Andrx' Fortamet (metformin extended-release) could be delayed by the company's newly filed Paragraph IV certifications against Bristol-Myers Squibb'sGlucophage XR patents
You may also be interested in...
Andrx Fortamet Clears FDA; Dosing Convenience Over Glucophage XR Will Be Focus
Patients will be able to achieve optimal daily metformin dose with half as many tablets as Glucophage XR and generics. Andrx is also touting the smaller size of the pills. Fortamet will launch in May.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.